
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is well-positioned in the biotechnology industry with promising pipeline products, including two MTA-cooperative PRMT5 inhibitors targeting various cancer types. The company is already in partnerships with major players in the industry, and its innovative approach to precision medicine could lead to successful treatment options for patients. Financially, the company has a strong cash position and potential for revenue growth through partnerships and its own drugs in development. These factors make Tango Therapeutics a strong investment opportunity.
Bears say
Tango Therapeutics is heavily reliant on its PRMT5 inhibitors for both its pipeline and revenue potential, which makes it vulnerable to competition from both established and emerging players in the market. The company also faces significant financial challenges, with the need to raise capital through dilutive financing options, potentially leading to ownership dilution for investors. While the company has a head start in its PRMT5/ KRAS inhibitor combination therapy, if results do not meet expectations, it could result in significant downside risk for the stock.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares